2,330 mcg / 0.10 mL
Daily Dose
Overview
What is Glow Stack?
GLOW is a pre-blended 70 mg vial combining three well-studied repair peptides: GHK-Cu, TB-500 (Thymosin Beta-4 fragment), and BPC-157. Each component targets complementary pathways in tissue regeneration — collagen synthesis, cell migration, and localised repair — making the combination a multi-mechanism approach to wound healing and recovery research.
The rationale for the blend: effective tissue repair requires concurrent action on structural rebuilding (GHK-Cu), cellular mobilisation (TB-500), and localised healing and anti-inflammatory signalling (BPC-157). Delivered as a single pre-blended vial, GLOW simplifies multi-peptide protocols into a single daily injection.
GHK-Cu: Collagen Synthesis
Stimulates collagen I, III, fibronectin, and decorin production. Modulates thousands of genes related to skin repair, angiogenesis, and tissue remodelling.
TB-500: Cell Migration
Binds actin to promote cell migration and cytoskeletal remodelling. Mobilises stem and progenitor cells to injury sites, accelerating angiogenesis and reducing fibrosis.
BPC-157: Localised Repair
Enhances VEGF/PDGF receptor signalling and nitric oxide pathways. Promotes fibroblast migration via the FAK-paxillin pathway for connective tissue repair.
Synergistic Action
Three complementary mechanisms — structural rebuilding, cellular mobilisation, and localised anti-inflammatory repair — operating simultaneously in a single injection.
Dosing Protocol
Dosing Schedule
Parameters documented in published preclinical and clinical research.
Research use only. The following documents parameters from published preclinical and clinical research. Not medical advice. Not for human consumption. Consult a licensed healthcare professional before any use.
| Phase | Dose | Volume (U-100) | Duration | Notes |
|---|
| Standard | 2,330 mcg (2.33 mg) | 10 units / 0.10 mL | Weeks 1–4 | Once daily SubQ. Delivers ~1.7 mg GHK-Cu + ~0.33 mg TB-500 + ~0.33 mg BPC-157 per injection. Reconstitute with 3.0 mL BAC water → 23.3 mg/mL. |
| Off cycle | — | — | 2–4 weeks | Rest period before repeating. Assess tissue response before restarting. |
Safety Profile
Safety & Side Effects
Generally Well Tolerated
All three components have favourable preclinical safety profiles
No androgenic effects from any component
Complementary, non-overlapping mechanisms reduce interaction risk
BPC-157 and TB-500 have extensive preclinical tolerability data
Potential Concerns
No human clinical trial data for the combined blend formulation
TB-500 is WADA-prohibited (Category S2)
Sourcing quality and blend accuracy critical — use COA-verified vendors only
Injection site reactions possible with daily SubQ administration
Research use onlyThis page is an educational reference. None of this constitutes medical advice. Consult a qualified professional before any use. All compounds are for research purposes only.
Recommended Source
Source your compounds at White Market Peptides
Use code PEPPERCALC10 for 10% off + free 2-day shipping over $200
Shop Now →